• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Earnings Scheduled For March 22, 2024

    3/22/24 5:40:22 AM ET
    $AGRX
    $ALOT
    $COE
    $HUMA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Computer peripheral equipment
    Technology
    Get the next $AGRX alert in real time by email

    Companies Reporting Before The Bell

    • Agile Therapeutics (NASDAQ:AGRX) is likely to report quarterly loss at $0.54 per share on revenue of $9.20 million.

    • 51 Talk Online Education (AMEX:COE) is projected to report earnings for its fourth quarter.

    • Star Equity Hldgs (NASDAQ:STRR) is likely to report quarterly loss at $0.08 per share on revenue of $9.15 million.

    • Hyzon Motors (NASDAQ:HYZN) is likely to report earnings for its fourth quarter.

    • Humacyte (NASDAQ:HUMA) is estimated to report quarterly loss at $0.24 per share on revenue of $60 thousand.

    • AstroNova (NASDAQ:ALOT) is likely to report earnings for its fourth quarter.

    • Sunlands Technology (NYSE:STG) is likely to report earnings for its fourth quarter.

    Companies Reporting After The Bell

    • Moleculin Biotech (NASDAQ:MBRX) is estimated to report earnings for its fourth quarter.

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AGRX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AGRX
    $ALOT
    $COE
    $HUMA

    CompanyDatePrice TargetRatingAnalyst
    Humacyte Inc.
    $HUMA
    8/27/2025$3.50Overweight
    Barclays
    Moleculin Biotech Inc.
    $MBRX
    6/9/2025$4.00Buy
    H.C. Wainwright
    Humacyte Inc.
    $HUMA
    5/14/2025$4.00Buy
    H.C. Wainwright
    Moleculin Biotech Inc.
    $MBRX
    2/12/2025Buy → Hold
    Maxim Group
    Humacyte Inc.
    $HUMA
    12/20/2024$12.00 → $15.00Buy
    H.C. Wainwright
    Humacyte Inc.
    $HUMA
    12/11/2023$6.00Buy
    H.C. Wainwright
    Humacyte Inc.
    $HUMA
    8/14/2023$2.75 → $3.50Underweight → Neutral
    Piper Sandler
    Humacyte Inc.
    $HUMA
    6/22/2023$6.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $AGRX
    $ALOT
    $COE
    $HUMA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Eberwein Jeffrey E. sold $39,794 worth of Series A Preferred Stock (4,365 units at $9.12) and bought $81,503 worth of shares (7,268 units at $11.21), increasing direct ownership by 27% to 1,007,824 units (SEC Form 4)

    4 - Star Equity Holdings, Inc. (0001210708) (Issuer)

    12/31/25 5:02:24 PM ET
    $STRR
    Professional Services
    Consumer Discretionary

    Chief Executive Officer Eberwein Jeffrey E. sold $173,974 worth of Series A Preferred Stock (18,635 units at $9.34) and bought $109,212 worth of shares (9,709 units at $11.25), increasing direct ownership by 23% to 1,000,556 units (SEC Form 4)

    4 - Star Equity Holdings, Inc. (0001210708) (Issuer)

    12/29/25 7:09:34 PM ET
    $STRR
    Professional Services
    Consumer Discretionary

    Chief Executive Officer Eberwein Jeffrey E. bought $2,999,991 worth of shares (287,631 units at $10.43) and sold $2,999,994 worth of Series A Preferred Stock (320,855 units at $9.35), increasing direct ownership by 15% to 810,217 units (SEC Form 4)

    4 - Star Equity Holdings, Inc. (0001210708) (Issuer)

    12/10/25 4:01:17 PM ET
    $STRR
    Professional Services
    Consumer Discretionary

    $AGRX
    $ALOT
    $COE
    $HUMA
    SEC Filings

    View All

    Moleculin Biotech Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - Moleculin Biotech, Inc. (0001659617) (Filer)

    2/5/26 11:55:04 AM ET
    $MBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Star Equity Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Star Equity Holdings, Inc. (0001210708) (Filer)

    2/3/26 4:46:36 PM ET
    $STRR
    Professional Services
    Consumer Discretionary

    Star Equity Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Star Equity Holdings, Inc. (0001210708) (Filer)

    1/20/26 7:10:29 PM ET
    $STRR
    Professional Services
    Consumer Discretionary

    $AGRX
    $ALOT
    $COE
    $HUMA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Humacyte Announces New U.S. Department of Defense Funding for Procurement of Bioengineered Blood Vessels

    DURHAM, N.C., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that the recently adopted FY 2026 U.S. Department of Defense (DoD) Appropriations Act includes dedicated funding to support the evaluation and incorporation of biologic vascular repair technologies for the warfighters suffering from traumatic vascular injuries. The FY2026 National Defense Authorization Act (NDAA), enacted in December 2025, stated in report language that DoD should "integrate FDA-approved breakthrough vascular repair technologies in traumatic extre

    2/9/26 8:00:00 AM ET
    $HUMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Moleculin to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial

    – Live video webcast on Wednesday, February 11th at 1:20 PM EST   HOUSTON, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), today announced that it will participate in the Corporate Connect Webinar Series hosted by Webull Financial being held virtually February 10-11, 2026. Details of the presentation are as follows: Date and Time: Wednesday, February 11, 2026 at 1:20 PM ESTPresenter: Walter Klemp, Founder, President, CEO and Chairman of MoleculinRegistration Link: Here About Webull Financial Webull Financial is a leading online brokerage platform committed to empowering self-directed investors with innovative tools and cutting-e

    2/5/26 9:15:00 AM ET
    $MBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Star Equity Holdings to Present at the Noble Capital Markets Emerging Growth Virtual Conference on February 4-5

    OLD GREENWICH, Conn., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Star Equity Holdings, Inc. (NASDAQ:STRR) formerly, Hudson Global, Inc. (NASDAQ:HSON) ("Star" or the "Company"), a diversified holding company, announced today that its management team will present and host one-on-one meetings with investors at Noble Capital Markets Emerging Growth Virtual Conference, which will take place from February 4-5, 2026. Star's main presentation is scheduled for Thursday, February 5 at 2:30pm ET. Investors can access the live presentation via: Virtual Equity Conference Registration Management will also host virtual one-on-one meetings with investors during both days. Investors can download a PDF copy of th

    1/29/26 8:30:00 AM ET
    $HSON
    $STRR
    Professional Services
    Consumer Discretionary

    $AGRX
    $ALOT
    $COE
    $HUMA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Eberwein Jeffrey E. was granted 5,703 shares, increasing direct ownership by 0.57% to 1,013,527 units (SEC Form 4)

    4 - Star Equity Holdings, Inc. (0001210708) (Issuer)

    1/16/26 4:43:05 PM ET
    $STRR
    Professional Services
    Consumer Discretionary

    Chief Executive Officer Eberwein Jeffrey E. sold $39,794 worth of Series A Preferred Stock (4,365 units at $9.12) and bought $81,503 worth of shares (7,268 units at $11.21), increasing direct ownership by 27% to 1,007,824 units (SEC Form 4)

    4 - Star Equity Holdings, Inc. (0001210708) (Issuer)

    12/31/25 5:02:24 PM ET
    $STRR
    Professional Services
    Consumer Discretionary

    Chief Executive Officer Eberwein Jeffrey E. sold $173,974 worth of Series A Preferred Stock (18,635 units at $9.34) and bought $109,212 worth of shares (9,709 units at $11.25), increasing direct ownership by 23% to 1,000,556 units (SEC Form 4)

    4 - Star Equity Holdings, Inc. (0001210708) (Issuer)

    12/29/25 7:09:34 PM ET
    $STRR
    Professional Services
    Consumer Discretionary

    $AGRX
    $ALOT
    $COE
    $HUMA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on Humacyte with a new price target

    Barclays initiated coverage of Humacyte with a rating of Overweight and set a new price target of $3.50

    8/27/25 8:22:05 AM ET
    $HUMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    H.C. Wainwright resumed coverage on Moleculin Biotech with a new price target

    H.C. Wainwright resumed coverage of Moleculin Biotech with a rating of Buy and set a new price target of $4.00

    6/9/25 7:52:11 AM ET
    $MBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright resumed coverage on Humacyte with a new price target

    H.C. Wainwright resumed coverage of Humacyte with a rating of Buy and set a new price target of $4.00

    5/14/25 11:33:51 AM ET
    $HUMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AGRX
    $ALOT
    $COE
    $HUMA
    Financials

    Live finance-specific insights

    View All

    AstroNova Reports 8.5% Sequential Growth in Revenue for Third Quarter Fiscal 2026

    Achieved revenue of $39.2 million in the quarter driven by sequential quarter growth in both Aerospace and Product Identification ("Product ID") Net income was $0.4 million, or $0.05 per diluted share; Non-GAAP net income was $1.5 million, or $0.20 per diluted share Adjusted EBITDA was $4.2 million, or 10.7% of sales Generated $3.4 million of operating cash in the quarter and $8.1 million year to date Strengthened balance sheet with debt reduced by $3.2 million in the quarter and $6.4 million year to date Refinanced lending agreement on favorable terms AstroNova, Inc. (NASDAQ:ALOT), a leading innovator in specialized print technology solutions, today announced financial results

    12/10/25 7:00:00 AM ET
    $ALOT
    Computer peripheral equipment
    Technology

    51Talk Online Education Group Announces Third Quarter 2025 Results

    SINGAPORE, Dec. 8, 2025 /PRNewswire/ -- 51Talk Online Education Group ("51Talk" or the "Company") (NYSE American: COE), a global online education platform with core expertise in English education, announced its unaudited results for the third quarter ended September 30, 2025. Third Quarter 2025 Financial and Operating Highlights Gross billings[1] for the third quarter of 2025 were US$40.5 million, a 104.6% growth from US$19.8 for the third quarter of 2024.Net revenues for the third quarter of 2025 were US$26.3 million, an 87.5% increase from US$14.0 million for the third quarter of 2024.The number of quarterly active students with attended lesson consumption for the third quarter of 2025 wa

    12/8/25 6:30:00 AM ET
    $COE
    Other Consumer Services
    Real Estate

    51Talk Online Education Group to Report Third Quarter 2025 Financial Results on Monday, December 8, 2025

    Earnings Call Scheduled for 8:00 a.m. ET on December 8, 2025 SINGAPORE, Dec. 3, 2025 /PRNewswire/ -- 51Talk Online Education Group ("51Talk", or the "Company") (NYSE:COE), a global online education platform with core expertise in English education, today announced that it will report its unaudited financial results for the third quarter ended September 30, 2025 on Monday, December 8, 2025, before the open of U.S. markets. The Company's management will host an earnings conference call at 8:00 a.m. U.S. Eastern Time on December 8, 2025 (9:00 p.m. Singapore/Beijing/Hong Kong time on December 8, 2025). Dial-in details for the earnings conference call are as follows: United States Toll: 1-888-34

    12/3/25 4:01:00 PM ET
    $COE
    Other Consumer Services
    Real Estate

    $AGRX
    $ALOT
    $COE
    $HUMA
    Leadership Updates

    Live Leadership Updates

    View All

    AstroNova Appoints Shawn Kravetz to Board of Directors

    AstroNova, Inc. (NASDAQ:ALOT), a leading innovator in specialized print technology solutions that enable data visualization, announced today that its Board of Directors has appointed Shawn Kravetz to the Board of Directors effective immediately, pursuant to the execution of a Cooperation Agreement between the Company and Askeladden Capital Management LLC ("Askeladden"). Mr. Kravetz, an independent director, will be a member of the Nominating and Governance Committee. Mr. Kravetz had been nominated by Askeladden to stand for election as a director. Darius G. Nevin, Executive Chair of AstroNova's Board of Directors, said, "I appreciate the constructive discussions with Askeladden and welcom

    8/21/25 8:00:00 AM ET
    $ALOT
    $SPRU
    Computer peripheral equipment
    Technology
    Auto Parts:O.E.M.
    Consumer Discretionary

    AstroNova Appoints Jorik E. Ittmann as President and Chief Executive Officer

    Leverages Mr. Ittmann's extensive print industry and international business experience Padraig Finn, with over 16 years in the print industry, promoted to Senior Vice President, Product Identification Tom Carll, Senior Vice President, Aerospace, Thomas DeByle, CFO, and Michael Natalizia, Chief Technology Officer, round out the Executive Leadership Team Darius G. Nevin appointed Executive Chairman AstroNova, Inc. (NASDAQ:ALOT), a leading innovator in specialized print technology solutions that enable data visualization, today announced that the Board of Directors has promoted Jorik E. Ittmann to President and CEO and appointed him to the Board of Directors, both to be effective

    8/4/25 9:00:00 AM ET
    $ALOT
    $DHR
    $VLTO
    Computer peripheral equipment
    Technology
    Industrial Machinery/Components
    Industrials

    Moleculin Engages Industry Veteran Adriano Treve to Explore Accelerated Strategic Partnerships

    40+ year career at Roche founded on dedication to bringing new innovative medicines to patients and making them accessible HOUSTON, July 17, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viral infections, today announced the appointment of Adriano Treve as a Strategic Advisor for partnerships. With over four decades of experience at Roche, Mr. Treve brings exceptional leadership and a deep understanding of global healthcare markets. He has held senior executive roles across diverse regions, including overseeing U.S. supply c

    7/17/25 8:25:00 AM ET
    $MBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGRX
    $ALOT
    $COE
    $HUMA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by 51Talk Online Education Group

    SC 13D/A - 51Talk Online Education Group (0001659494) (Subject)

    12/17/24 4:07:04 PM ET
    $COE
    Other Consumer Services
    Real Estate

    Amendment: SEC Form SC 13D/A filed by Humacyte Inc.

    SC 13D/A - Humacyte, Inc. (0001818382) (Subject)

    11/20/24 7:10:08 PM ET
    $HUMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13D/A filed by Humacyte Inc.

    SC 13D/A - Humacyte, Inc. (0001818382) (Subject)

    11/18/24 4:10:14 PM ET
    $HUMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care